U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H44O2
Molecular Weight 400.6371
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CALCIFEDIOL ANHYDROUS

SMILES

C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C

InChI

InChIKey=JWUBBDSIWDLEOM-DTOXIADCSA-N
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1

HIDE SMILES / InChI

Molecular Formula C27H44O2
Molecular Weight 400.6371
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 5 / 5
E/Z Centers 2
Optical Activity UNSPECIFIED

Description

Calcifediol (25-Hydroxyvitamin D3 or 25-hydroxycholecalciferol) is a biologically active vitamin D3 metabolite. It is concluded that the liver is the major if not the only physiologic site of hydroxylation of vitamin D3 into calcifediol. Calcifediol is a prohormone of the active form of vitamin D3, calcitriol (1,25-dihydroxyvitamin D3). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis. RAYALDEE (calcifediol) extended-release capsules is indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease.

CNS Activity

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In Vivo Use Guide
The initial dose of RAYALDEE (calcifediol) extended-release capsules is 30 mcg administered orally once daily at bedtime. Serum calcium should be below 9.8 mg/dL before initiating treatment. Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and intact parathyroid hormone (PTH) 3 months after starting therapy or changing dose. Increase the dose to 60 mcg once daily after 3 months if intact PTH is above the treatment goal. Ensure serum calcium is below 9.8 mg/dL, phosphorus is below 5.5 mg/dL and 25-hydroxyvitamin D is below 100 ng/mL before increasing the dose. Suspend dosing if intact PTH is persistently abnormally low, serum calcium is consistently above the normal range or serum 25­ hydroxyvitamin D is consistently above 100 ng/mL
Route of Administration: Oral
In Vitro Use Guide
Vitamin D metabolites down-regulated stimulated IL-8 only in those hyperinflammatory monocyte-derived macrophages, and only when used at high doses (>100 nM for Calcifediol).
Substance Class Chemical
Created
by admin
on Tue Mar 06 11:00:10 UTC 2018
Edited
by admin
on Tue Mar 06 11:00:10 UTC 2018
Record UNII
T0WXW8F54E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CALCIFEDIOL ANHYDROUS
Common Name English
CALCIFEDIOL, ANHYDROUS
Common Name English
CALCIFEDIOL,ANHYDROUS
VANDF  
Common Name English
CALCIFEDIOL [MI]
Common Name English
CALCIFEDIOL [INN]
Common Name English
CALCIFEDIOL,ANHYDROUS [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC A11CC06
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
Code System Code Type Description
INN
3057
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY
MERCK INDEX
M2911
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY Merck Index
DRUG BANK
DB00146
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY
PUBCHEM
5283731
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY SWITZERF
NCI_THESAURUS
C77155
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY
EVMPD
SUB06045MIG
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY
EPA CompTox
19356-17-3
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY
RXCUI
1855064
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY
ECHA (EC/EINECS)
242-990-9
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY
CAS
19356-17-3
Created by admin on Tue Mar 06 11:00:10 UTC 2018 , Edited by admin on Tue Mar 06 11:00:10 UTC 2018
PRIMARY